处于“十字路口”的基因治疗,将何去何从?
[1]E. Valeur, etal.New modalities for challenging targets in drug discovery, Angew.Chem.Int. Ed. (2017) 56 (35): 10294–10323.
[2]H. Wu, etal.Pharmaceutical Biotechnology: Fundamentals and Applications, SpringerInternational Publishing, Cham. (2019), pp. 323–355
[3]W. Xu, etal.RNA interference technology, Compr. Biotechnol. (2019) 5:560–575.
[4]A. Khurana, etal.Yttrium oxide nanoparticles reduce the severity of acute pancreatitiscaused by cerulein hyperstimulation, Nanomedicine. (2019) 18:54–65.
[5]R. Goswami, G. etal.Gene therapy leaves a vicious cycle, Front. Oncol. (2019) 9: 297.
[6]S. Ghosh, etal.Viral vector systems for gene therapy: a comprehensive literaturereview of progress and biosafety challenges, Appl. Biosaf. (2020) 25:7–18.
[7]Parambi DGT, etal.Gene Therapy Approach with an Emphasis on Growth Factors: Theoreticaland Clinical Outcomes in Neurodegenerative Diseases. Mol Neurobiol.(2022) 59(1):191-233.
[8]Arabi F, etal.Gene therapy clinical trials, where do we go? An overview. BiomedPharmacother. (2022) 153:113324.
[9]Gene therapy at the crossroads. Nat Biotechnol. (2022) 40(5):621.
[10]Jayakumar R, etal.Chitosan conjugated DNA nanoparticles in gene therapy. CarbohydrPolym. (2010) 79:1–8.
[11]Cring MR, etal.Gene therapy and gene correction: targets, progress, and challengesfor treating human diseases. Gene Ther. (2022) 29(1-2):3-12.
[12]Gyorgy B, etal.Rescue of hearing by gene delivery to inner-ear hair cells usingexosome-associated AAV. Mol Ther. (2017) 25:379–91.
E.N.D
为促进细胞与基因治疗领域的合作交流,更好的服务广大读者朋友,微信公众号“细胞与基因治疗领域”团队组建了专业的细胞与基因治疗行业交流群(涉及DNA药物、RNA药物和细胞治疗等方面),长按下方二维码,添加小编微信进群。由于申请人数较多,添加微信时请备注:院校/企事业单位名称—专业/职务—姓名。如果您是PI/ 教授/主管及以上职务,还请注明。
往期文章推荐:
mRNA疫苗两巨头对簿公堂,Moderna起诉辉瑞和BioNTech侵犯专利,复必泰会不会受影响?
细胞治疗提速包 | GMP级CD3/CD28单抗偶联磁珠邀您免费试用
深度解析|基于mRNA的癌症疫苗:从mRNA药物分子设计到免疫反应
一文读懂体外基因疗法中最常用载体----慢病毒载体现状与进展
眼科基因疗法研发热情提升,全球布局企业不断增加,研发突破不断
基因疗法又一里程碑|全球首个直接注入大脑的AAV基因疗法获批上市